Evidence map›Paper›PMID 26559836›Full record

ArticleJournal of virology2016

The C Terminus of the Core β-Ladder Domain in Japanese Encephalitis Virus Nonstructural Protein 1 Is Flexible for Accommodation of Heterologous Epitope Fusion.

Li-Chen Yen, Jia-Teh Liao, Hwei-Jen Lee, Wei-Yuan Chou, Chun-Wei Chen, Yi-Ling Lin, Ching-Len Liao

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Li-Chen YenDepartment of Biochemistry, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Jia-Teh LiaoDepartment of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Hwei-Jen LeeDepartment of Biochemistry, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Wei-Yuan ChouDepartment of Biochemistry, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Chun-Wei ChenDepartment of Biochemistry, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Yi-Ling LinInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Republic of China.
Ching-Len LiaoDepartment of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, Republic of China National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan, Republic of China chinglen@gmail.com.
National Defense Medical Center · TWInstitute of Biomedical Sciences, Academia Sinica · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledNS1 is the only nonstructural protein that enters the lumen of the endoplasmic reticulum (ER), where NS1 is glycosylated, forms a dimer, and is subsequently secreted during flavivirus replication as dimers or hexamers, which appear to be highly immunogenic to the infected host, as protective immunity can be elicited against homologous flavivirus infections. Here, by using a trans-complementation assay, we identified the C-terminal end of NS1 derived from Japanese encephalitis virus (JEV), which was more flexible than other regions in terms of housing foreign epitopes without a significant impact on virus replication. This mapped flexible region is located in the conserved tip of the core β-ladder domain of the multimeric NS1 structure and is also known to contain certain linear epitopes, readily triggering specific antibody responses from the host. Despite becoming attenuated, recombinant JEV with insertion of a neutralizing epitope derived from enterovirus 71 (EV71) into the C-terminal end of NS1 not only could be normally released from infected cells, but also induced dual protective immunity for the host to counteract lethal challenge with either JEV or EV71 in neonatal mice. These results indicated that the secreted multimeric NS1 of flaviviruses may serve as a natural protein carrier to render epitopes of interest more immunogenic in the C terminus of the core β-ladder domain. IMPORTANCE: The positive-sense RNA genomes of mosquito-borne flaviviruses appear to be flexible in terms of accommodating extra insertions of short heterologous antigens into their virus genes. Here, we illustrate that the newly identified C terminus of the core β-ladder domain in NS1 could be readily inserted into entities such as EV71 epitopes, and the resulting NS1-epitope fusion proteins appeared to maintain normal virus replication, secretion ability, and multimeric formation from infected cells. Nonetheless, such an insertion attenuated the recombinant JEV in mice, despite having retained the brain replication ability observed in wild-type JEV. Mother dams immunized with recombinant JEV expressing EV71 epitope-NS1 fused proteins elicited neutralizing antibodies that protected the newborn mice against lethal EV71 challenge. Together, our results implied a potential application of JEV NS1 as a viral carrier protein to express a heterologous epitope to stimulate dual/multiple protective immunity concurrently against several pathogens.

Indexed as

Virus ReplicationAnimalsDisease Models, AnimalEncephalitis, JapaneseEncephalitis Virus, JapaneseEnterovirus A, HumanEnterovirus InfectionsEpitopesFemaleMice, Inbred ICRRecombinant Fusion ProteinsSurvival AnalysisVaccines, SyntheticViral Nonstructural ProteinsViral VaccinesEpitopesNS1 protein, FlavivirusRecombinant Fusion ProteinsVaccines, SyntheticViral Nonstructural ProteinsViral Vaccines

Identifiers

PMID26559836
PMCPMC4719612
OpenAlexW2217537343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.